Positionspapier: Empfehlungen zur Anwendung von Omalizumab bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC)

Zusammenfassung

Hintergrund Die chronische Rhinosinusitis mit Nasenpolypen (CRSwNP) ist eine multifaktorielle entzündliche Erkrankung der paranasalen Schleimhäute, der als Endotyp meistens eine TH2-Inflammation zugrunde liegt. IgE-Antikörper spielen dabei eine wichtige Rolle. Der anti-IgE-Antikörper Omalizumab wurde im August 2020 für die Therapie der schweren CRSwNP zugelassen.

Methoden In einer Literatursuche wurde die Immunologie der CRSwNP analysiert und die Evidenz zur Wirkung von Omalizumab bei dieser Erkrankung ermittelt durch Recherchen in Medline, Pubmed sowie den nationalen und internationalen Studien- und Leitlinien-Registern und der Cochrane Library.

Ergebnisse Basierend auf diesen Angaben aus der internationalen Literatur werden von einem Expertengremium Empfehlungen für die Anwendung von Omalizumab bei CRSwNP im deutschen Gesundheitssystem gegeben.

Schlussfolgerung Omalizumab ist zugelassen für Patienten ab 18 Jahren mit schwerer chronischer Rhinosinusitis mit Nasenpolypen als Zusatztherapie zu intranasalen Kortikosteroiden (INCS), wenn durch eine Therapie mit INCS keine ausreichende Krankheitskontrolle erzielt werden kann.

Schlüsselwörter

chronische Rhinosinusitis - Endotyp-Klassifizierung - nasale Polypen - CRSwNP - Biologika - Omalizumab - COVID-19

Publication History

Article published online:
30 September 2021

• Literatur

• 1 Ohnmacht C. Microbiota, regulatory T cell subsets, and allergic disorders. Allergo J Int 2016; 25: 114-123
• 2 Ono S, Kabashima K. Novel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT). Allergo J Int 2015; 24: 170-179
• 3 Klimek L, Koennecke M, Hagemann J. et al [Immunology of chronic rhinosinusitis with nasal polyps as a basis for treatment with biologicals]. HNO 2019; 67: 15-26
• 4 Koennecke M, Klimek L, Mullol J. et al Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo journal international 2018; 27: 56-65
• 5 Galli SJ, Metz M, Starkl P. et al Mast cells and IgE in defense against lethality of venoms: Possible “benefit” of allergy. Allergo J Int 2020; 29: 46-62
• 6 Kabesch M. Epigenetic determinants of allergy and tolerance. Allergo Journal 2016; 25: 32-37
• 7 Sutton BJ, Davies AM. Structure and dynamics of IgE-receptor interactions: FcepsilonRI and CD23/FcepsilonRII. Immunol Rev 2015; 268: 222-235
• 8 Hastan D, Fokkens WJ, Bachert C. et al Chronic rhinosinusitis in Europe – an underestimated disease. A GA²LEN study. Allergy 2011; 66: 1216-1223 . doi:343917 de-38m
• 9 Hirsch AG, Stewart WF, Sundaresan AS. et al Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample. Allergy 2017; 72: 274-281
• 10 Ostovar A, Fokkens WJ, Vahdat K. et al Epidemiology of chronic rhinosinusitis in Bushehr, southwestern region of Iran: a GA2LEN study. Rhinology 2019; 57: 43-48
• 11 Shi JB, Fu QL, Zhang H. et al Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities. Allergy 2015; 70: 533-539
• 12 Stuck BA, Beule A, Jobst D. et al [Guideline for “rhinosinusitis”-long version: S2k guideline of the German College of General Practitioners and Family Physicians and the German Society for Oto-Rhino-Laryngology, Head and Neck Surgery]. HNO 2018; 66: 38-74
• 13 Fokkens WJ, Lund VJ, Mullol J. et al European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl 2012; 23: 3p preceding table of contents, 1-298
• 14 Fokkens WJ, Lund VJ, Mullol J. et al EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50: 1-12
• 15 Rosenfeld RM. Clinical practice guideline on adult sinusitis. Otolaryngology – head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery 2007; 137: 365-377 . doi:46829 de-38m
• 16 Agarwal A, Spath D, Sherris DA. et al Therapeutic Antibodies for Nasal Polyposis Treatment: Where Are We Headed?. Clinical reviews in allergy & immunology 2019; 59: 141-149 . doi:351562 de-38m
• 17 Franzese CB. The Role of Biologics in the Treatment of Nasal Polyps. Immunology and allergy clinics of North America 2020; 40: 295-302 . doi:133755 de-38m
• 18 Klimek L, Förster-Ruhrmann U, Becker S. et al Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC). Laryngo-Rhino-Otol 2020; 99 (08) 511-527 . doi:204768 de-38m
• 19 Jutel M, Van de Veen W, Agache I. et al Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergology international: official journal of the Japanese Society of Allergology 2013; 62: 425-433 . doi:482779 de-38m
• 20 Klimek L, Bachert C, Pfaar O. et al ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie select 2019; 3: 22-50 . doi:1016429 de-38m
• 21 Klimek L, Brehler R, Hamelmann E. et al CME Zertifizierte Fortbildung. Entwicklung der subkutanen Allergen-Immuntherapie (Teil 2): präventive Aspekte der SCIT und Innovationen. Allergo J Int 2019; 28: 107–119: Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations/CME-Fragebogen. Allergo-Journal 2019; 28: 31/45 . doi:317060 de-38m
• 22 Klimek L, Brehler R, Hamelmann E. et al CME-Fortbildung. Entwicklung der subkutanen Allergen- Immuntherapie (Teil 1): von den Anfängen zu immunologisch orientierten Therapiekonzepten. Evolution of subcutaneous allergen immunotherapy (part 1): from first developments to mechanism-driven therapy concepts. Allergo J Int 2019;28:78-95 / CME-Fragebogen. Allergo-Journal 2019; 28: 26-47 . doi:317060 de-38m
• 23 Klimek L, Casper I, Bergmann KC. Positionspapier. Die Therapie der allergischen Rhinitis in der Routineversorgung: evidenzbasierte Nutzenbewertung der kombinierten Anwendung mehrerer Wirkstoffe. Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. Allergologie 2020; 43: 476 . doi:50376de-38m
• 24 Ade R, Rehm M. A prediction of dust mite populations in different categories of housing quality in Auckland, New Zealand. Allergo Journal International 2020; 29: 187-198
• 25 Pitsios C, Pantavou K, Terreehorst I. et al Use of allergy tests to identify dietary and environmental triggers of eosinophilic esophagitis: protocol for a systematic review. Allergo Journal International 2020; 29: 280-283
• 26 Seidenberg J, Stelljes G, Lange L. et al Airlines provide too little information for allergy sufferers!. Allergo Journal International 2020; 29: 262-279
• 27 Johns CB, Laidlaw TM. Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease. Am J Rhinol Allergy 2014; 28: 287-289
• 28 Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis research & therapy 2009; 11: 257 . doi:10.1186/ar2843. doi:599177de-38m
• 29 Plager DA, Kahl JC, Asmann YW. et al Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis. PloS one 2010; 5: e11450 . doi:10.1371/journal.pone.0011450
• 30 Van Zele T, Claeys S, Gevaert P. et al Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 61: 1280-1289 . doi:343917 de-38m
• 31 Zygmunt B, Veldhoen M. T helper cell differentiation more than just cytokines. Advances in immunology 2011; 109: 159-196 . doi:43811 de-38m
• 32 Kopf M, Le Gros G, Bachmann M. et al Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245-248 . doi:43481 de-38m
• 33 Ouyang W, Ranganath SH, Weindel K. et al Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity 1998; 9: 745-755 . doi:351310 de-38m
• 34 Danielsen A, Tynning T, Brokstad KA. et al Interleukin 5, IL6, IL12, IFN-gamma, RANTES and Fractalkine in human nasal polyps, turbinate mucosa and serum. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 2006; 263: 282-289 . doi:219928 de-38m
• 35 Derycke L, Eyerich S, Van Crombruggen K. et al Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps. PloS one 2014; 9: e97581 . doi:10.1371/journal.pone.0097581
• 36 Li Z, Zhang Y, Sun B. Current understanding of Th2 cell differentiation and function. Protein & cell 2011; 2: 604-611
• 37 Prussin C, Yin Y, Upadhyaya B. T(H)2 heterogeneity: Does function follow form?. The Journal of allergy and clinical immunology 2010; 126: 1094-1098 . doi:37848 de-38m
• 38 Eckl-Dorna J, Pree I, Reisinger J. et al The majority of allergen-specific IgE in the blood of allergic patients does not originate from blood-derived B cells or plasma cells. Clin Exp Allergy 2012; 42: 1347-1355
• 39 Bachert C, Wagenmann M, Hauser U. et al IL-5 synthesis is upregulated in human nasal polyp tissue. The Journal of allergy and clinical immunology 1997; 99: 837-842 . doi:37848 de-38m
• 40 Bachert C, Gevaert P, Holtappels G. et al Nasal polyposis: from cytokines to growth. American journal of rhinology 2000; 14: 279-290 . doi:348449 de-38m
• 41 Hurst SM, Wilkinson TS, McLoughlin RM. et al Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705-714 . doi:351310 de-38m
• 42 Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. Journal of immunology (Baltimore, Md: 1950) 2005; 175: 3463-3468 . doi:60148 de-38m
• 43 Kaplanski G, Marin V, Montero-Julian F. et al IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends in immunology 2003; 24: 25-29 . doi:485944 de-38m
• 44 Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition requiring effective anti-inflammatory treatment. Current opinion in otolaryngology & head and neck surgery 2013; 21: 23-30 . doi:351458 de-38m
• 45 Kato A. Immunopathology of chronic rhinosinusitis. Allergology international: official journal of the Japanese Society of Allergology 2015; 64: 121-130 . doi:482779 de-38m
• 46 Lam EPS, Kariyawasam HH, Rana BMJ. et al IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. The Journal of allergy and clinical immunology 2016; 137: 1514-1524 . doi:37848 de-38m
• 47 Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunological reviews 2008; 223: 20-38 . doi:29355 de-38m
• 48 Kim DK, Jin HR, Eun KM. et al The role of interleukin-33 in chronic rhinosinusitis. Thorax 2017; 72: 635-645 . doi:283139 de-38m
• 49 Reh DD, Wang Y, Ramanathan M. et al Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. American journal of rhinology & allergy 2010; 24: 105-109 . doi:791174 de-38m
• 50 Bachert C, Zhang N, Hellings PW. et al Endotype-driven care pathways in patients with chronic rhinosinusitis. The Journal of allergy and clinical immunology 2018; 141: 1543-1551 . doi:37848 de-38m
• 51 De Schryver E, Devuyst L, Derycke L. et al Local immunoglobulin e in the nasal mucosa: clinical implications. Allergy, asthma & immunology research 2015; 7: 321-331 . doi:822656 de-38m
• 52 Gevaert P, Nouri-Aria KT, Wu H. et al Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy 2013; 68: 55-63 . doi:343917 de-38m
• 53 Cherry WB, Yoon J, Bartemes KR. et al A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. The Journal of allergy and clinical immunology 2008; 121: 1484-1490 . doi:37848 de-38m
• 54 Mjösberg JM, Trifari S, Crellin NK. et al Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nature immunology 2011; 12: 1055-1062 . doi:483981 de-38m
• 55 Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. The Journal of allergy and clinical immunology 2016; 138: 1243-1251 . doi:37848 de-38m
• 56 Halderman AA, Lane AP. Immunomodulators in the Treatment of Nasal Polyposis. Advances in oto-rhino-laryngology 2016; 79: 103-113 . doi:29578 de-38m
• 57 Naclerio R, Baroody F, Bachert C. et al Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop. The journal of allergy and clinical immunology In practice 2020; 8: 1532-1549.e1531 . doi:917835 de-38m
• 58 Ho J, Bailey M, Zaunders J. et al Cellular comparison of sinus mucosa vs polyp tissue from a single sinus cavity in chronic rhinosinusitis. International forum of allergy & rhinology 2015; 5: 14-27 . doi:868989 de-38m
• 59 Ho J, Bailey M, Zaunders J. et al Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology 2015; 45: 394-403 . doi:175877 de-38m
• 60 Liao B, Liu JX, Li ZY. et al Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy 2018; 73: 1459-1469 . doi:343917 de-38m
• 61 Philpott CM, Erskine S, Hopkins C. et al Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respiratory research 2018; 19: 129 . doi:986957 de-38m
• 62 Wu D, Bleier BS, Li L. et al Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History. J Allergy Clin Immunol Pract 2018; 6: 1297-1305 e1291
• 63 Khan A, Vandeplas G, Huynh TMT. et al The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2018; 57: 32-42 . doi:341423 de-38m
• 64 Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. Journal of asthma and allergy 2016; 9: 45-53 . doi:797791 de-38m
• 65 Tomassen P, Vandeplas G, Van Zele T. et al Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. The Journal of allergy and clinical immunology 2016; 137: 1449-1456.e1444 . doi:37848 de-38m
• 66 Lin DC, Chandra RK, Tan BK. et al Association between severity of asthma and degree of chronic rhinosinusitis. American journal of rhinology & allergy 2011; 25: 205-208 . doi:791174 de-38m
• 67 Shaw DE, Sousa AR, Fowler SJ. et al Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. The European respiratory journal 2015; 46: 1308-1321 . doi:145674 de-38m
• 68 De Greve G, Hellings PW, Fokkens WJ. et al Endotype-driven treatment in chronic upper airway diseases. Clinical and translational allergy 2017; 7: 22 . doi:871682 de-38m
• 69 Seys SF, Scheers H, Van den Brande P. et al Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respiratory research 2017; 18: 39 . doi:10.1186/s12931-017-0524-y. doi:986957 de-38m
• 70 Zhang Y, Derycke L, Holtappels G. et al Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps. Allergy 2018; 74: 131-140 . doi:343917 de-38m
• 71 Bidder T, Sahota J, Rennie C. et al Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology 2018; 56: 42-45 . doi:341423 de-38m
• 72 Green RH, Brightling CE, Woltmann G. et al Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879 . doi:283139 de-38m
• 73 GINA. Global Strategy for Asthma Management and Prevention (2019 update). 2019 www.ginasthma.org
• 74 Orlandi RR, Kingdom TT, Hwang PH. et al International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. International forum of allergy & rhinology 2016; 6 (Suppl. 01) S22-209 . doi:868989 de-38m
• 75 Pundir V, Pundir J, Lancaster G. et al Role of corticosteroids in Functional Endoscopic Sinus Surgery – a systematic review and meta-analysis. Rhinology 2016; 54: 3-19 . doi:341423 de-38m
• 76 Voorham J, Xu X, Price DB. et al Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy 2018; 74: 273-283 . doi:343917 de-38m
• 77 Kirsche H, Klimek L. ASS-Intoleranz-Syndrom und persistierende Rhinosinusitis: Differenzialdiagnostik und Therapie. Hno 2015; 63: 357-363 . doi:36872 de-38m
• 78 Klimek L, Pfaar O. Aspirin intolerance: does desensitization alter the course of the disease?. Immunology and allergy clinics of North America 2009; 29: 669-675 . doi:133755 de-38m
• 79 Bölke G, Church MK, Bergmann KC. Comparison of extended intervals and dose reduction of omalizumab for asthma control. Allergo Journal International 2019; 28: 1-4
• 80 Ong KY. What’s new in the Global Initiative for Asthma 2018 report and beyond. Allergo Journal International 2019; 28: 63-72
• 81 Raulf M, Sander I, Brüning T. et al Occupational asthma due to tampico fiber bystander exposure in a brush production company — case report and literature review. Allergo Journal International 2019; 28: 73-77
• 82 Hopkins C, Surda P, Bast F. et al Prevention of chronic rhinosinusitis. Rhinology 2018; 56: 307-315 . doi:341423 de-38m
• 83 Kilty SJ, Lasso A, Mfuna-Endam L. et al Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps. Rhinology 2018; 56: 155-157 . doi:341423 de-38m
• 84 Rudmik L, Soler ZM, Hopkins C. et al Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology 2016; 54: 117-128 . doi:341423 de-38m
• 85 Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert review of clinical immunology 2017; 13: 425-437 . doi:704218 de-38m
• 86 Sanofi-Aventis_Deutschland_GmbH. Dupixent® 300 mg Injektionslösung in einer Fertigspritze, R.L.S. GmbH – Fachinformation. Rote Liste Service GmbH. Frankfurt: 2020: 21
• 87 Forster-Ruhrmann U, Stergioudi D, Pierchalla G. et al Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology 2020; 58: 226-232 . doi:341423 de-38m
• 88 Ren L, Zhang N, Zhang L. et al Biologics for the treatment of chronic rhinosinusitis with nasal polyps – state of the art. The World Allergy Organization journal 2019; 12: 100050 . doi:1059287 de-38m
• 89 Tsetsos N, Goudakos JK, Daskalakis D. et al Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology 2018; 56: 11-21 . doi:341423 de-38m
• 90 Presta LG, Lahr SJ, Shields RL. et al Humanization of an antibody directed against IgE. Journal of immunology (Baltimore, Md: 1950) 1993; 151: 2623-2632 . doi:60148 de-38m
• 91 MacGlashan DW, Bochner BS, Adelman DC. et al Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. Journal of immunology (Baltimore, Md: 1950) 1997; 158: 1438-1445 . doi:60148 de-38m
• 92 Novartis_Pharma_GmbH. Xolair ® 150 mg Injektionslösung, R.L.S. GmbH – Fachinformation. Rote Liste Service GmbH Frankfurt 2019. p. 9.
• 93 Saini SS, Bindslev-Jensen C, Maurer M. et al Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. The Journal of investigative dermatology 2015; 135: 67-75 . doi:56869 de-38m
• 94 Pinto JM, Mehta N, DiTineo M. et al A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010; 48: 318-324 . doi:341423 de-38m
• 95 Gevaert P, Calus L, Van Zele T. et al Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. The Journal of allergy and clinical immunology 2013; 131: 110-116.e111 . doi:37848 de-38m
• 96 Romano C, Pace G, Sellitto A. et al Omalizumab as a last resort therapy for intractable, severe chronic allergic rhinosinusitis. Allergo Journal International 2019; 28: 99-102
• 97 Agache I, Rocha C, Beltran J. et al Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020; 75: 1043-1057 . doi:343917 de-38m
• 98 Serrano-Candelas E, Martinez-Aranguren R, Valero A. et al Comparable actions of omalizumab on mast cells and basophils. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology 2016; 46: 92-102 . doi:175877 de-38m
• 99 Lin H, Boesel KM, Griffith DT. et al Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. The Journal of allergy and clinical immunology 2004; 113: 297-302 . doi:37848 de-38m
• 100 Prussin C, Griffith DT, Boesel KM. et al Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. The Journal of allergy and clinical immunology 2003; 112: 1147-1154 . doi:37848 de-38m
• 101 Djukanović R, Wilson SJ, Kraft M. et al Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. American journal of respiratory and critical care medicine 2004; 170: 583-593 . doi:295090 de-38m
• 102 Sahota J, Bidder T, Livingston R. et al Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life*. Rhinology Online 2018; 1: 147-153
• 103 Roche H-L. A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2). 2019 In. 09.01.2020 ed. https://clinicaltrials.gov/ct2/show/NCT03280537
• 104 Roche H-L. A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (POLYP 1). 2019 https://clinicaltrials.gov/ct2/show/NCT03280550
• 105 Gevaert P, Omachi TA, Corren J. et al Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. The Journal of allergy and clinical immunology 2020; 146: 595-605 . doi:37848 de-38m
• 106 DeutschesArztportal. Der Ratgeber zur wirtschaftlichen Verordnung – Rabattvertrags-Check. In. DeutschesArztportal; 2021
• 107 Bachert C, Gevaert P, Hellings P. Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. The journal of allergy and clinical immunology In practice 2017; 5: 1512-1516 . doi:917835 de-38m
• 108 Kim DW, Cho SH. Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine. Allergy, asthma & immunology research 2017; 9: 299-306 . doi:822656 de-38m
• 109 Untersmayr E, Förster-Waldl E, Bonelli M. et al Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe: Ein Positionspapier der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und des Ärzteverbands Deutscher Allergologen (AeDA). Allergo Journal: interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin: Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung 2021; 30: 34-47 . doi:317060 de-38m
• 110 Altrichter S, Wöhrl S, Horak F. et al Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines. Allergo journal international 2021; 1-7
• 111 Klimek L, Pfaar O, Worm M. Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI. Use of biologicals in allergic and type-2 inflammatory diseases in times of the current COVID-19 pandemic – Position paper of AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI. Allergologie 2020; 43: 255 . doi:50376 de-38m
• 112 Riggioni C, Comberiati P, Giovannini M. et al A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy 2020; 75: 2503-2541 . doi:343917 de-38m
• 113 Dorsch W, Ring J. Anti-inflammatory substances from onions could be an option for treatment of COVID-19-a hypothesis. Allergo journal international 2020; 29: 284-285
• 114 Jakob T, Klimek L. Allergologie in Zeiten von COVID-19. Allergo Journal 2020; 29: 3-3 . doi:317060 de-38m
• 115 Klimek L, Bergmann KC, Brehler R. et al Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe: Ein Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA), der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA) und der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI). Allergo Journal: interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin: Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung 2021; 30: 22-43 . doi:317060 de-38m
• 116 Klimek L, Jutel M, Akdis C. et al Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy 2020; 75: 1546-1554 . doi:343917 de-38m
• 117 Klimek L, Novak N, Hamelmann E. et al Schwere allergische Reaktionen nach COVID-19-Impfung mit dem Impfstoff von Pfizer/BioNTech in Großbritannien und USA: Stellungnahme der deutschen allergologischen Gesellschaften AeDA (Ärzteverband Deutscher Allergologen), DGAKI (Deutsche Gesellschaft für Allergologie und klinische Immunologie) und GPA (Gesellschaft für Pädiatrische Allergologie und Umweltmedizin). Allergo Journal: interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin: Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung 2021; 30: 24-29 . doi:317060 de-38m
• 118 Klimek L, Pfaar O, Worm M. et al Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie. Allergo Journal 2020; 29: 17-25 . doi:317060 de-38m
• 119 Klimek L, Worm M, Lange L. et al Management von Anaphylaxie-gefährdeten Patienten wahrend der COVID-19-Pandemie: Ein Positionspapier des Arzteverbandes Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft fur Allergologie und klinische Immunologie (DGAKI)B, der Gesellschaft fur Padiatrische Allergologie und Umweltmedizin (GPA)C und des Deutschen Allergie- und Asthmabundes (DAAB)D. WHO; 2020
• 120 Pfaar O, Klimek L, Hamelmann E. et al COVID-19-Impfungen von Patienten mit Allergien und Typ2-entzündlichen Erkrankungen bei gleichzeitiger Antikörpertherapie (Biologika): Ein Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) und dem Ärzteverband Deutscher Allergologen (AeDA). Allergo Journal: interdisziplinare Zeitschrift fur Allergologie und Umweltmedizin: Organ der Deutschen Gesellschaft fur Allergie- und Immunitatsforschung 2021; 30: 24-33 . doi:317060 de-38m
• 121 Pfaar O, Klimek L, Jutel M. et al COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy 2020; 76: 648-676 . doi:343917 de-38m